Holen Sie sich die Stockscreener-App
94.83
0.02%
-0.02
Handel nachbörslich:
94.71
-0.12
-0.13%
Schlusskurs vom Vortag:
$94.85
Offen:
$94.77
24-Stunden-Volumen:
1.27M
Relative Volume:
0.69
Marktkapitalisierung:
$7.17B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-24.01
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+0.47%
1M Leistung:
+36.29%
6M Leistung:
+123.50%
1J Leistung:
+81.77%
1-Tages-Spanne:
$94.56
$94.94
1-Wochen-Bereich:
$94.29
$95.02
52-Wochen-Spanne:
$33.19
$95.02
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
94.83 | 7.19B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-08-25 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-07 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-21 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-03-28 | Eingeleitet | Truist | Buy |
| 2024-03-04 | Bestätigt | Needham | Buy |
| 2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-08-21 | Eingeleitet | TD Cowen | Outperform |
| 2022-08-02 | Eingeleitet | Stifel | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Needham | Buy |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-08 | Eingeleitet | William Blair | Outperform |
| 2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Buy |
| 2019-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Fortgesetzt | Guggenheim | Buy |
| 2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2016-06-13 | Eingeleitet | Citigroup | Buy |
| 2016-06-13 | Eingeleitet | Guggenheim | Buy |
| 2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
Merus (MRUS) Shares Promising Interim Findings from Phase 2 Canc - GuruFocus
Merus announces initial interim data from phase 2 trial of petosemtamab - TipRanks
Merus reports promising early data for petosemtamab in colorectal cancer By Investing.com - Investing.com Nigeria
Merus Announces Publication of an Abstract on Petosemtamab - GlobeNewswire
36 patients: Merus' petosemtamab shows preliminary antitumor activity and manageable safety in mCRC phase 2 - Stock Titan
Will Merus N.V. stock continue upward momentumWeekly Investment Report & Fast Gain Stock Tips - newser.com
Why Merus N.V. is moving todayEntry Point & Free Technical Confirmation Trade Alerts - newser.com
Can Merus N.V. stock double in next 5 yearsTrade Exit Summary & Stepwise Trade Signal Implementation - newser.com
Merus Announces Petosemtamab in Metastatic Colorectal - GlobeNewswire
Merus to present petosemtamab data for colorectal cancer at conference By Investing.com - Investing.com Nigeria
Merus N.V. to Present Two Abstracts on Petosemtamab at AACR-NCI-EORTC Conference in Boston - Quiver Quantitative
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - The Manila Times
Phase 2 interim data: Merus' petosemtamab to be presented in plenary at AACR Oct 24; poster on cancer stem cells - Stock Titan
Will Merus N.V. outperform the market2025 Trading Recap & High Accuracy Trade Signal Alerts - newser.com
Will Merus N.V. stock deliver better than expected guidance2025 Macro Impact & Technical Confirmation Alerts - newser.com
Can you recover from losses in Merus N.V.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Will Merus N.V. stock sustain high P E ratiosJuly 2025 Weekly Recap & Weekly High Potential Alerts - newser.com
Will Merus N.V. price bounce be sustainable2025 Biggest Moves & Daily Stock Trend Watchlist - newser.com
Deals In Depth: September 2025 - insights.citeline.com
Merus N.V. announces proposed public offering of common shares - MSN
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
Merus (NASDAQ:MRUS) Hits New 12-Month HighHere's Why - MarketBeat
Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Automated trading signals detected on Merus N.V.July 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Is Merus N.V. (2GH) stock safe for risk averse investorsWall Street Watch & Accurate Entry/Exit Alerts - newser.com
What margin trends mean for Merus N.V. stockNew Guidance & Daily Price Action Insights - newser.com
Is Merus NV a good long term investmentTrading Psychology Tips & Market Monitoring and Alerts - earlytimes.in
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders - GlobeNewswire Inc.
Merus NV stock hits all-time high at 94.56 USD By Investing.com - Investing.com Nigeria
Merus NV stock hits all-time high at 94.56 USD - Investing.com
Will Merus N.V. stock see PE expansion2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
Why Merus N.V. (2GH) stock could outperform next yearJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise - Investing.com Nigeria
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise By Investing.com - Investing.com South Africa
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inside INdiana Business - FinancialContent
Merus (NASDAQ:MRUS) Downgraded by Leerink Partnrs to "Hold" - MarketBeat
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com
Truist Securities raises Genmab stock price target to $49 on Merus acquisition - Investing.com
Is Merus N.V. building a consolidation baseQuarterly Profit Review & Short-Term High Return Strategies - newser.com
Leerink Partners Downgrades Merus to Market Perform From Outperform, Adjusts PT to $97 From $95 - MarketScreener
MRUS Downgraded to Market Perform by Leerink Partners with Raise - GuruFocus
What MACD signals say about Merus N.V.Profit Target & Consistent Profit Alerts - newser.com
Leerink Partners downgrades Merus stock to Market Perform on Genmab deal - Investing.com
What’s the recovery path for long term holders of Merus N.V.2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com
How big funds are accumulating Merus N.V. (2GH) stockRecession Risk & Verified Entry Point Detection - newser.com
Relative strength of Merus N.V. in sector analysisJuly 2025 Recap & Fast Entry Momentum Alerts - newser.com
Will Merus N.V. (2GH) stock maintain strong growth2025 Institutional Moves & Community Verified Swing Trade Signals - newser.com
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Merus N V-Aktie (MRUS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):